Alector (NASDAQ: ALEC), a late-stage clinical biotechnology company specializing in neurodegeneration therapies, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, June 10, 2024, at 8:40 am ET. Investors can access a live webcast of the discussion through Alector's website investor section, with a replay available for 90 days following the event. The company focuses on developing treatments to combat neurodegenerative disease progression.
Alector (NASDAQ: ALEC), un'azienda biotecnologica in fase avanzata specializzata in terapie per la neurodegenerazione, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità di Goldman Sachs. Il management della società prenderà parte a un incontro informale martedì 10 giugno 2024 alle 8:40 ET. Gli investitori potranno seguire la diretta streaming della discussione nella sezione investitori del sito web di Alector, con la possibilità di rivedere la registrazione per 90 giorni dopo l'evento. L'azienda si dedica allo sviluppo di trattamenti per contrastare la progressione delle malattie neurodegenerative.
Alector (NASDAQ: ALEC), una empresa biotecnológica en etapa avanzada especializada en terapias para la neurodegeneración, anunció su participación en la 46ª Conferencia Global Anual de Salud de Goldman Sachs. La dirección de la compañía participará en una charla informal el martes 10 de junio de 2024 a las 8:40 am ET. Los inversores podrán acceder a una transmisión en vivo de la discusión a través de la sección de inversores en el sitio web de Alector, con una repetición disponible durante 90 días después del evento. La empresa se centra en desarrollar tratamientos para combatir la progresión de las enfermedades neurodegenerativas.
Alector(NASDAQ: ALEC)는 신경퇴행성 질환 치료제 개발에 특화된 후기 임상 단계의 생명공학 회사로, 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 6월 10일 화요일 오전 8시 40분(동부 시간)에 진행되는 소규모 대화에 참여할 예정입니다. 투자자들은 Alector 웹사이트의 투자자 섹션을 통해 라이브 웹캐스트를 시청할 수 있으며, 행사 후 90일 동안 다시보기 서비스도 제공됩니다. 이 회사는 신경퇴행성 질환의 진행을 억제하는 치료제 개발에 집중하고 있습니다.
Alector (NASDAQ : ALEC), une société biotechnologique en phase avancée spécialisée dans les thérapies contre la neurodégénérescence, a annoncé sa participation à la 46e conférence annuelle mondiale sur la santé de Goldman Sachs. La direction de l'entreprise participera à une discussion informelle le mardi 10 juin 2024 à 8h40, heure de l'Est. Les investisseurs pourront suivre la diffusion en direct de cette discussion via la section investisseurs du site web d'Alector, avec une rediffusion disponible pendant 90 jours après l'événement. La société se concentre sur le développement de traitements visant à ralentir la progression des maladies neurodégénératives.
Alector (NASDAQ: ALEC), ein biotechnologisches Unternehmen in der Spätphase, das sich auf Therapien gegen Neurodegeneration spezialisiert hat, gab seine Teilnahme an der 46. jährlichen Global Healthcare Conference von Goldman Sachs bekannt. Das Management des Unternehmens wird am Dienstag, den 10. Juni 2024, um 8:40 Uhr ET an einem informellen Gespräch teilnehmen. Investoren können die Live-Übertragung der Diskussion über den Investorenbereich der Alector-Website verfolgen, mit einer Wiederholung, die 90 Tage nach der Veranstaltung verfügbar ist. Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen zur Bekämpfung des Fortschreitens neurodegenerativer Erkrankungen.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.
A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.
About Alector Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
